Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (81-90 of 237) with videos related to

Pageof 24
Sort By:
Nature Reviews. Clinical Oncology|February 2, 2011
Mitosis is not a key target of microtubule agents in patient tumorsEdina Komlodi-Pasztor, Dan Sackett, Julia Wilkerson, et al.
The Lancet. Oncology|January 5, 2025
Evidence for a reduction in number of cycles of immune checkpoint inhibitorsAbdul-Hamid Bazarbachi, Nicola Magrini, Zeba Aziz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2012
Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationaleEdina Komlodi-Pasztor, Dan L Sackett, Antonio Tito Fojo
The Oncologist|May 13, 2020
Emerging Therapeutic Implications of STK11 Mutation: Case SeriesBahar Laderian, Prabhjot Mundi, Tito Fojo, et al.
The Oncologist|July 25, 2013
Clinical trial results: Sharing results, speeding discoveriesAntonio Tito Fojo, Susan E Bates, Bruce A Chabner
The Oncologist|March 22, 2015
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trialsMauricio Burotto, Elisabet E Manasanch, Julia Wilkerson, et al.
Biochimica Et Biophysica Acta|April 3, 2007
A database study that identifies genes whose expression correlates, negatively or positively, with 5-year survival of cancer patientsWilfred D Stein, Thomas Litman, Tito Fojo, et al.
Cancer Biology & Therapy|May 29, 2015
Multiplying therapies and reducing toxicity in metastatic melanomaPaul R Massey, Vinay Prasad, William D Figg, et al.
The Oncologist|October 7, 2025
Highlights of ASCO 2025Brandon DaSilva, Alfred I Neugut, Tito Fojo, et al.
The Oncologist|October 2, 2008
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantageWilfred D Stein, James Yang, Susan E Bates, et al.
Pageof 24

Showing results (81-90 of 237) with videos related to

Sort By:
Pageof 24
Nature Reviews. Clinical Oncology|February 2, 2011
Mitosis is not a key target of microtubule agents in patient tumorsEdina Komlodi-Pasztor, Dan Sackett, Julia Wilkerson, et al.
The Lancet. Oncology|January 5, 2025
Evidence for a reduction in number of cycles of immune checkpoint inhibitorsAbdul-Hamid Bazarbachi, Nicola Magrini, Zeba Aziz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2012
Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationaleEdina Komlodi-Pasztor, Dan L Sackett, Antonio Tito Fojo
The Oncologist|May 13, 2020
Emerging Therapeutic Implications of STK11 Mutation: Case SeriesBahar Laderian, Prabhjot Mundi, Tito Fojo, et al.
The Oncologist|July 25, 2013
Clinical trial results: Sharing results, speeding discoveriesAntonio Tito Fojo, Susan E Bates, Bruce A Chabner
The Oncologist|March 22, 2015
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trialsMauricio Burotto, Elisabet E Manasanch, Julia Wilkerson, et al.
Biochimica Et Biophysica Acta|April 3, 2007
A database study that identifies genes whose expression correlates, negatively or positively, with 5-year survival of cancer patientsWilfred D Stein, Thomas Litman, Tito Fojo, et al.
Cancer Biology & Therapy|May 29, 2015
Multiplying therapies and reducing toxicity in metastatic melanomaPaul R Massey, Vinay Prasad, William D Figg, et al.
The Oncologist|October 7, 2025
Highlights of ASCO 2025Brandon DaSilva, Alfred I Neugut, Tito Fojo, et al.
The Oncologist|October 2, 2008
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantageWilfred D Stein, James Yang, Susan E Bates, et al.
Pageof 24